Tesamorelin

Tesamorelin is a synthetic analog of human Growth Hormone Releasing Hormone (GHRH) consisting of all 44 amino acids of native GHRH(1-44) with the addition of a trans-3-hexenoic acid group at the N-terminus. This lipophilic modification enhances metabolic stability by protecting the peptide from DPP-IV enzymatic cleavage at the N-terminal dipeptide, which is the primary degradation pathway for native GHRH. The result is a GHRH analog with improved pharmacokinetic properties while maintaining full receptor binding activity.

Like other GHRH analogs, tesamorelin acts through the GHRH receptor on anterior pituitary somatotropes. Receptor activation stimulates the Gs-cAMP-PKA signaling cascade, enhancing both GH gene transcription and GH secretion through calcium-dependent exocytosis. The preserved negative feedback mechanisms ensure that GH release occurs in physiological pulsatile patterns, maintaining the body's natural regulatory framework.

Tesamorelin's most distinctive research contribution is in the field of lipodystrophy - specifically visceral adipose tissue (VAT) accumulation. Clinical studies demonstrated significant and sustained reductions in trunk fat and visceral adiposity, while preserving or improving subcutaneous fat distribution and lean body mass. The mechanism involves GH's well-characterized lipolytic effects, particularly on visceral adipocytes which express higher densities of GH receptors compared to subcutaneous fat.

Hepatic research represents a rapidly growing application area. Studies have shown that tesamorelin reduces intrahepatic lipid content and may improve markers of liver inflammation and fibrosis. These effects are particularly relevant to MASLD (metabolic dysfunction-associated steatotic liver disease) research, where hepatic fat accumulation drives disease progression. The mechanism involves both direct GH effects on hepatic lipid metabolism and indirect effects through improved insulin sensitivity and reduced visceral fat-derived inflammatory signals.

Cardiovascular metabolic research has documented improvements in triglyceride levels, inflammatory biomarkers (including C-reactive protein and IL-6), and carotid intima-media thickness - a surrogate marker for atherosclerotic burden. These findings suggest potential cardiovascular benefits beyond body composition changes.

Cognitive research has explored the relationship between GH/IGF-1 axis stimulation and executive function, memory, and information processing speed, with some studies suggesting improvements in cognitive domains affected by aging.

For reconstitution, dissolve in bacteriostatic water. Store at 2-8°C and use within 4 weeks.

PeptidesDirect tesamorelin is verified at ≥98% purity. Certificate of Analysis included. EU-shipped.